Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and the full year 2022. Investors may be concerned that ...
The latest price target for Rain Enhancement (NASDAQ:RAIN) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.00 expecting RAIN to fall to within 12 months (a ...
The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a ...
or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback